Investigational Drug Details
| Drug ID: | D040 |
| Drug Name: | BIO89-100 |
| Synonyms: | -- |
| Type: | Biological drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | FGF21 analog |
| Therapeutic Category: | Improve insulin resistance; Enhance lipid metabolism |
| Clinical Trial Progress: | Phase 2 on-going (NCT04929483) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0172 | NCT04929483 | Phase 2 | Recruiting | No Results Available | June 4, 2021 | January 25, 2022 | Details |
| L0274 | NCT05022693 | Phase 1 | Completed | No Results Available | August 16, 2021 | March 2, 2022 | Details |
| L0460 | NCT04048135 | Phase 1/Phase 2 | Not recruiting | No Results Available | 04/08/2019 | 10 August 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title |
|---|